fluorouracil has been researched along with Proteinuria in 13 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the present study, either modified IFL regimen (modified irinotecan, fluorouracil and leucovorin, mIFL) alone or in combination with bevacizumab was used to treat patients with metastatic colorectal cancer (CRC)." | 5.14 | Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. ( Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q, 2010) |
| "We report the case of a 39-year-old para-4 gravida-4 who received polychemotherapy 5-fluorouracil 600 mg/m2, cyclophosphamide 600 mg/m2 and epirubicin 50 mg/m2 for invasive breast cancer (pT2N2Mo) with extensive metastatic involvement of all 23 axillary lymph nodes removed at 29 gestational weeks." | 3.69 | Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy. ( Hofmann, J; Müller, T; Steck, T, 1996) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "Case 2: A 72-year-old man underwent sigmoid colon cancer resection with duodenal infiltration." | 1.72 | [Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration]. ( Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H, 2022) |
| " The primary objective was to investigate the incidence of adverse drug reactions, particularly those of interest for bevacizumab." | 1.43 | Bevacizumab safety in Japanese patients with colorectal cancer. ( Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016) |
| " The clinical efficacy and bevacizumab-related adverse reactions were observed." | 1.39 | [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. ( Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013) |
| " Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events." | 1.37 | Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011) |
| " Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion." | 1.27 | Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. ( Dodge, RK; Forastiere, AA; Goren, MP; Horowitz, ME; Kamen, BA; Pratt, CB; Viar, MJ; Wright, RK, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Nakura, M | 1 |
| Nojima, K | 1 |
| Yamazaki, H | 1 |
| Takenaka, S | 1 |
| Watanabe, T | 1 |
| Takeshita, M | 1 |
| Sasaki, S | 1 |
| Fujimura, T | 1 |
| Dote, S | 1 |
| Shiwaku, E | 1 |
| Kohno, E | 1 |
| Fujii, R | 1 |
| Mashimo, K | 1 |
| Morimoto, N | 1 |
| Yoshino, M | 1 |
| Odaira, N | 1 |
| Ikesue, H | 1 |
| Hirabatake, M | 1 |
| Takahashi, K | 1 |
| Takahashi, M | 1 |
| Takagi, M | 1 |
| Nishiuma, S | 1 |
| Ito, K | 1 |
| Shimato, A | 1 |
| Itakura, S | 1 |
| Takahashi, Y | 2 |
| Negoro, Y | 1 |
| Shigemori, M | 1 |
| Watanabe, H | 1 |
| Hayasaka, D | 1 |
| Nakao, M | 1 |
| Tasaka, M | 1 |
| Goto, E | 1 |
| Kataoka, N | 1 |
| Yokomizo, A | 1 |
| Kobayashi, A | 1 |
| Nakata, Y | 1 |
| Miyake, M | 1 |
| Hayashi, Y | 1 |
| Yamamoto, Y | 1 |
| Hirata, T | 1 |
| Azuma, K | 1 |
| Makihara, K | 1 |
| Fukui, R | 1 |
| Tokutome, A | 1 |
| Yagisawa, K | 1 |
| Honda, S | 1 |
| Meguro, Y | 1 |
| Suzuki, S | 1 |
| Yamaguchi, D | 1 |
| Miyata, H | 1 |
| Kobayashi, Y | 1 |
| Guo, X | 1 |
| Liu, TS | 1 |
| Yu, YY | 1 |
| Zhou, YH | 1 |
| Chen, Y | 1 |
| Zhuang, RY | 1 |
| Cui, YH | 1 |
| Feliu, J | 1 |
| Salud, A | 1 |
| Safont, MJ | 1 |
| García-Girón, C | 1 |
| Aparicio, J | 1 |
| Losa, F | 1 |
| Bosch, C | 1 |
| Escudero, P | 1 |
| Casado, E | 1 |
| Jorge, M | 1 |
| Bohn, U | 1 |
| Pérez-Carrión, R | 1 |
| Carmona, A | 1 |
| Custodio, AB | 1 |
| Maurel, J | 1 |
| Hatake, K | 1 |
| Doi, T | 1 |
| Uetake, H | 1 |
| Ishihara, Y | 1 |
| Shirao, K | 1 |
| Balduzzi, A | 1 |
| Montagna, E | 1 |
| Bagnardi, V | 1 |
| Torrisi, R | 1 |
| Bertolini, F | 1 |
| Mancuso, P | 1 |
| Scarano, E | 1 |
| Viale, G | 1 |
| Veronesi, P | 1 |
| Cardillo, A | 1 |
| Orlando, L | 1 |
| Goldhirsch, A | 1 |
| Colleoni, M | 1 |
| Luo, W | 1 |
| Liao, WJ | 1 |
| Ma, L | 1 |
| Huang, YT | 1 |
| Shi, M | 1 |
| Wen, Q | 1 |
| Wang, XN | 1 |
| Sogabe, S | 1 |
| Komatsu, Y | 1 |
| Yuki, S | 1 |
| Kusumi, T | 1 |
| Hatanaka, K | 1 |
| Nakamura, M | 1 |
| Kato, T | 1 |
| Miyagishima, T | 1 |
| Hosokawa, A | 1 |
| Iwanaga, I | 1 |
| Sakata, Y | 1 |
| Asaka, M | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 1 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Park, JS | 1 |
| Gordon, MS | 1 |
| Cunningham, D | 1 |
| Müller, T | 1 |
| Hofmann, J | 1 |
| Steck, T | 1 |
| Goren, MP | 1 |
| Forastiere, AA | 1 |
| Wright, RK | 1 |
| Horowitz, ME | 1 |
| Dodge, RK | 1 |
| Kamen, BA | 1 |
| Viar, MJ | 1 |
| Pratt, CB | 1 |
| Nekulová, M | 1 |
| Mechl, Z | 1 |
| Kerpel-Fronius, S | 1 |
| Skalková, D | 1 |
| Sopková, B | 1 |
1 review available for fluorouracil and Proteinuria
| Article | Year |
|---|---|
Managing patients treated with bevacizumab combination therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
2 trials available for fluorouracil and Proteinuria
| Article | Year |
|---|---|
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
10 other studies available for fluorouracil and Proteinuria
| Article | Year |
|---|---|
[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorec | 2022 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic N | 2023 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Bevacizumab safety in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2016 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; A | 2009 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Eclampsia after polychemotherapy for nodal-positive breast cancer during pregnancy.
Topics: Adult; Antibiotics, Antineoplastic; Anticonvulsants; Antihypertensive Agents; Antineoplastic Combine | 1996 |
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Topics: Acetylglucosaminidase; Acute Disease; Adult; Aminopeptidases; Antineoplastic Combined Chemotherapy P | 1987 |
The excretion of urinary enzymes, proteins and creatinine in patients receiving cisplatinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Enzymes; Fluorouracil; gamma- | 1987 |